Press "Enter" to skip to content

Merck’s treatment for urinary, abdominal infections gets FDA approval

FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Linden, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid

(Reuters) – The U.S. Food and Drug Administration has approved Merck & Co Inc’s combination treatment for complicated forms of urinary tract and abdominal infections, the drugmaker said on Wednesday.

The treatment, Recarbrio, is approved for patients over 18 years who have limited or no alternative treatment options for treating these infections, Merck said.

Reporting by Aakash Jagadeesh Babu and Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber

Our Standards:The Thomson Reuters Trust Principles.